Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | NOS3 | P29474 | 3/20 | 0.53 |
| ▸ | NOS1 | P29475 | 3/20 | 0.53 |
| ▸ | NOS2 | P35228 | 3/20 | 0.53 |
| ▸ | DPP4 | P27487 | 3/20 | 0.51 |
| ▸ | FAP | Q12884 | 2/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.51 |
| ▸ | POLQ | O75417 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42976 | 1.00 | PPARG (0.53) | PPARGPPARAALPIPKMPTGS1 | |
| SCHEMBL42975 | 1.00 | PPARG (0.53) | PPARGPPARAALPIPKMPTGS1 | |
| SCHEMBL29410813 | 1.00 | PPARG (0.53) | PPARGPPARAALPIPKMPTGS1 | |
| SCHEMBL19143671 | 0.87 | NOS3 (0.50) | PPARGPPARAALPIPKMPTGS1 | |
| SCHEMBL14489706 | 0.87 | NOS3 (0.52) | PPARGPPARAALPIPKMPTGS1 | |
| SCHEMBL20038753 | 0.87 | NOS3 (0.52) | PPARGPPARAALPIPKMPTGS1 | |
| SCHEMBL5328323 | 0.86 | NOS3 (0.46) | PPARGPPARAALPIPKMPTGS1 | |
| SCHEMBL16938502 | 0.85 | DPP4 (0.50) | PPARGPPARADPP4FAPDPP8 | |
| SCHEMBL9492298 | 0.84 | PPARG (0.57) | PPARGPPARADPP4POLQDPP7 | |
| SCHEMBL26966057 | 0.84 | POLQ (0.48) | PPARGPPARAALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464324-B1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | FERRING BV (NL) | 2021-04-07 | — | — | EP | claimed |
| US-20200102348-A1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | FERRING B.V. (NL) | 2020-04-02 | — | — | US | claimed |
| US-10344054-B2 | Angiotensin-1-receptor antagonists | FERRING B.V. (NL) | 2019-07-09 | — | — | US | claimed |
| EP-3464324-A1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | Ferring B.V. (NL) | 2019-04-10 | — | — | EP | claimed |
| US-20170349629-A1 | Angiotensin-1-Receptor Antagonists | FERRING B.V. (NL) | 2017-12-07 | — | — | US | claimed |
| WO-2017207760-A1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | FERRING B.V. (NL) | 2017-12-07 | — | — | WO | claimed |
| EP-2036918-A1 | PEPTIDE DERIVATIVE | Vexon, Inc. (JP) | 2009-03-18 | — | — | EP | claimed |
| US-20080009448-A1 | Peptide Derivative | VEXON, INC. (50%) (JP) | 2008-01-10 | — | — | US | claimed |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | TRANSFERT PLUS LP (CA) | 2026-03-26 | — | — | US | disclosed |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-12371461-B2 | Nemo coiled coil mimics and methods of using same | NEW YORK UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| US-7232803-B2 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2007-06-19 | — | — | US | disclosed |
| US-20060194700-A1 | Corrosion inhibitor systems for low, moderate and high temperature fluids and methods for making and using same | WEATHERFORD/LAMB | 2006-08-31 | — | — | US | disclosed |
| US-20060116296-A1 | Shale Inhibition additive for oil/gas down hole fluids and methods for making and using same | CLEARWATER INTERNATIONAL, L.L.C. | 2006-06-01 | — | — | US | disclosed |
| US-6890902-B2 | Cytotoxic modified lactoferrin peptides | ALPHARMA AS (NO) | 2005-05-10 | — | — | US | disclosed |
| US-20030195144-A1 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2003-10-16 | — | — | US | disclosed |
| US-20030022821-A1 | Bioactive peptides | ALPHARMA AS | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | PPARG 3246/4885PPARA 2209/4885ALPI 4083/4885 |
| US-20170349629-A1 | Angiotensin-1-Receptor Antagonists | AGTR1, AGTR2, REN | PPARG 977/4885PPARA 1134/4885ALPI 3555/4885 |
| US-20200102348-A1 | ANGIOTENSIN-1-RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | PPARG 977/4885PPARA 1134/4885ALPI 3555/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | PPARG 4812/4885PPARA 4523/4885ALPI 563/4885 |
| US-12371461-B2 | Nemo coiled coil mimics and methods of using same | COIL, CALCOCO2, NCAPH | PPARG 4002/4885PPARA 4497/4885ALPI 4559/4885 |
| US-10344054-B2 | Angiotensin-1-receptor antagonists | AGTR1, AGTR2, AGT | PPARG 1035/4885PPARA 1097/4885ALPI 3362/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | PPARG 4634/4885PPARA 4154/4885ALPI 818/4885 |
| US-20030195144-A1 | Antimicrobial compounds and formulations | LPO, CLPTM1, VIP | PPARG 1529/4885PPARA 638/4885ALPI 1907/4885 |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | VSIG8, MICA, CD74 | PPARG 4616/4885PPARA 4835/4885ALPI 2844/4885 |
| US-20030022821-A1 | Bioactive peptides | VIP, LITAF, LNPEP | PPARG 2764/4885PPARA 1562/4885ALPI 712/4885 |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | DDX21, PHAX, RBX1 | PPARG 3003/4885PPARA 3778/4885ALPI 4755/4885 |
| US-20080009448-A1 | Peptide Derivative | ARGLU1, NGLY1, NPR3 | PPARG 4811/4885PPARA 4517/4885ALPI 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.